MEAF6

Across TCGA pan-cancer cohorts, MEAF6 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MEAF6’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MEAF6 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MEAF6 is over-expressed in tumor, although a few such as LUAD and PDAC show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where MEAF6 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MEAF6 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	+0.135	<.001	6	view →
LUAD	Male	All	−0.109	<.001	4	view →
LSCC	All	All	+0.082	.001	4	view →
PDAC	All	All	−0.244	.020	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

MEAF6–CCRCC

Open the CCRCC breakdown →